AL-37350A

AL-37350A
Clinical data
Other names	4,5-DHP-AMT; 4,5-Dihydropyrano-AMT; 4,5-Dihydropyrano-α-methyltryptamine
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code	None;
Identifiers
	IUPAC name (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole;
CAS Number	362603-40-5 ;
PubChem CID	10331436;
IUPHAR/BPS	160;
ChemSpider	8506896 ;
UNII	KT54N4CC67;
ChEMBL	ChEMBL133455 ;
CompTox Dashboard (EPA)	DTXSID501350247 DTXSID10438239, DTXSID501350247 ;
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.311 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O2c1ccc3c(c1CCC2)c(c[nH]3)C[C@@H](N)C;
	InChI InChI=1S/C14H18N2O/c1-9(15)7-10-8-16-12-4-5-13-11(14(10)12)3-2-6-17-13/h4-5,8-9,16H,2-3,6-7,15H2,1H3/t9-/m0/s1 ; Key:VVHJUSGIUWQPIT-VIFPVBQESA-N ;
	(what is this?) (verify)

AL-37350A, also known as 4,5-dihydropyrano-α-methyltryptamine (4,5-DHP-AMT), is a serotonin receptor agonist and tricyclic tryptamine derivative related to the psychedelic tryptamine 5-MeO-AMT.^[1]^[2] It acts as a potent and selective agonist for the serotonin receptor 5-HT_2A, with a K_i of 2.0 nM, and moderate selectivity over the related 5-HT_2B and 5-HT_2C receptors.^[1]^[2] The drug has been shown to have ocular hypotensive activity in animal models, suggesting it may be useful for the treatment of glaucoma.^[2] AL-37350A was first described in the scientific literature by Jesse May and colleagues in 2003.^[1]^[2]